Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:GSTC OTCMKTS:NRXGQ OTCMKTS:OREXQ NYSE:UPC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSTCGlobeStar Therapeutics$0.00$0.00▼$0.00$124K1.952,503 shsN/ANRXGQNephroGenex$0.00$0.00▼$0.21$36KN/A26,223 shs2,000 shsOREXQOrexigen Therapeutics$0.01+35.9%$0.01$0.00▼$0.16$100K4.9880,439 shs60,300 shsUPCUniverse Pharmaceuticals$3.76+7.9%$4.27$2.51▼$2,400.00$161K1.43177,259 shs38,326 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSTCGlobeStar Therapeutics0.00%0.00%0.00%-50.00%-90.00%NRXGQNephroGenex0.00%0.00%0.00%0.00%0.00%OREXQOrexigen Therapeutics0.00%0.00%0.00%0.00%0.00%UPCUniverse Pharmaceuticals+6.42%-9.14%-11.45%-3.60%-99.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGSTCGlobeStar TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/AN/AN/AN/AN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSTCGlobeStar Therapeutics 0.00N/AN/AN/ANRXGQNephroGenex 0.00N/AN/AN/AOREXQOrexigen Therapeutics 0.00N/AN/AN/AUPCUniverse Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSTCGlobeStar TherapeuticsN/AN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/AN/AN/AN/AN/AOREXQOrexigen Therapeutics$33.71M0.00N/AN/AN/A∞UPCUniverse Pharmaceuticals$19.29M0.01N/AN/A$163.50 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSTCGlobeStar Therapeutics-$1.95MN/A0.00N/AN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/A0.00N/AN/AN/AN/AN/AN/AOREXQOrexigen Therapeutics-$24.52MN/A0.00∞N/AN/AN/AN/AN/AUPCUniverse Pharmaceuticals-$6.16MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGSTCGlobeStar TherapeuticsN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/AN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSTCGlobeStar Therapeutics0.01%NRXGQNephroGenexN/AOREXQOrexigen TherapeuticsN/AUPCUniverse Pharmaceuticals0.18%Insider OwnershipCompanyInsider OwnershipGSTCGlobeStar Therapeutics2.50%NRXGQNephroGenexN/AOREXQOrexigen Therapeutics13.30%UPCUniverse Pharmaceuticals57.38%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSTCGlobeStar Therapeutics11.24 billion1.21 billionNot OptionableNRXGQNephroGenex1,70012.95 millionN/ANot OptionableOREXQOrexigen Therapeutics13218.89 millionN/ANot OptionableUPCUniverse Pharmaceuticals22043,000731,000Not OptionableNRXGQ, UPC, GSTC, and OREXQ HeadlinesRecent News About These CompaniesPharma Playbook: What Practitioners Can Learn from Early UPC LitigationMay 14, 2025 | ipwatchdog.comIUniverse Pharmaceuticals Reports Full Year 2024 EarningsMay 3, 2025 | finance.yahoo.comUniverse Pharmaceuticals INC Announces Share Consolidation Effective March 24, 2025March 20, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | gurufocus.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | investing.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | globenewswire.comUniverse Pharmaceuticals Approves Share Consolidation at Extraordinary MeetingMarch 11, 2025 | tipranks.comUniverse Pharmaceuticals INC Faces Potential Delisting from Nasdaq Due to Delinquent Annual Report FilingFebruary 25, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual ReportFebruary 25, 2025 | globenewswire.comUniverse Pharmaceuticals proposes revised share consolidationFebruary 11, 2025 | msn.comUniverse Pharmaceuticals (NASDAQ:UPC) Stock, Short Interest ReportFebruary 10, 2025 | benzinga.comUniverse Pharmaceuticals INC.: Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing RequestFebruary 6, 2025 | finanznachrichten.deUPC’s Unexpected Plunge: What’s Next?February 5, 2025 | bovnews.comBUniverse Pharmaceuticals gets Nasdaq delisting noticeFebruary 4, 2025 | markets.businessinsider.comUniverse Pharmaceuticals INC Faces Nasdaq Delisting Due to Low Share PriceFebruary 3, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing RequestFebruary 3, 2025 | globenewswire.comUniverse Pharmaceuticals announces shareholder meetingJanuary 30, 2025 | msn.comUniverse Pharmaceuticals stock hits 52-week low at $0.48 amid steep declineJanuary 29, 2025 | msn.comUniverse Pharmaceuticals Inc (UPC) Stock: A Deeper Look at Its True PotentialDecember 29, 2024 | bovnews.comBUniverse Pharmaceuticals Files Registration for 37.5 Million SharesDecember 14, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Stocks to Buy Ahead of the Upcoming Earnings SeasonBy Chris Markoch | July 11, 2025View 3 Stocks to Buy Ahead of the Upcoming Earnings Season3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingBy Chris Markoch | June 29, 2025View 3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingAlphabet: Technical Momentum Is Starting to TurnBy Ryan Hasson | July 10, 2025View Alphabet: Technical Momentum Is Starting to TurnCyclical Rebound or False Start for These 3 Stocks?By Gabriel Osorio-Mazilli | July 17, 2025View Cyclical Rebound or False Start for These 3 Stocks?NRXGQ, UPC, GSTC, and OREXQ Company DescriptionsGlobeStar Therapeutics OTCMKTS:GSTCGlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in Richland, Washington.NephroGenex OTCMKTS:NRXGQNephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.Orexigen Therapeutics OTCMKTS:OREXQ$0.0053 +0.00 (+35.90%) As of 05/31/2019Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Universe Pharmaceuticals NYSE:UPC$3.76 +0.28 (+7.90%) Closing price 03:58 PM EasternExtended Trading$3.73 -0.02 (-0.67%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors Palantir Bulls and Bears Set for an August Showdown 3 Reasons Palo Alto Networks Is Becoming a Wall Street Favorite Vertical Aerospace Stock Trades at Discount After VX4 Milestone GameStop: Clarity Brings Renewed Confusion for Meme Stock Analysts Are Backing Qualcomm: Is a Breakout Coming? TSLA Earnings Week: Can Tesla Break Through $350? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
